18 Jul 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Controversy stricken British pharmaceutical major, GlaxoSmithKline has had to answer more than one scandalous question in the last few days as investigations into the bribery allegations have unfolded.
Now, the Chinese police have raised concerns about GSK's China operations head, Mr Mark Reilly's absence from the country, in spite of the ongoing investigations.
It has been reported that Mr Reilly left the country on June 27, merely days after the Changsha police in China announced investigations into the bribery case.
GSK faces allegations of bribing doctors and government officials through money and sexual favors to artificially boost sale prices of drugs in the Chinese markets.
The company has claimed that it would co-operate with the Chinese investigations and has said that the claims made against them were ‘shameful.'